Skip to content

A randomized controlled study of rTMS improving depression in Parkinson's disease

A randomized controlled of rTMS improving depression in Parkinson's disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044421
Enrollment
Unknown
Registered
2021-03-18
Start date
2021-04-30
Completion date
Unknown
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease with depression

Interventions

control group:sham stimulation

Sponsors

Xinhua Hospital, Affiliated to Shanghai JiaoTong University, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age ranging from 45 and 75 years. 2) clinical diagnosis with idiopathic Parkinson's disease according to the MDS 2015 criteria. 3) H&Y stage between 1 and 3 grades. 4) having depressive symptoms according to ICD -10 criteria for depression. 5) The patient or his legal guardian has agreed to participate in the trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Having cognitive impairment; 2) having psychiatric symptoms; 3) having histories of chronic organic dysfunction( heart, lung ,liver and kidney); 4) having other neurologic disease; 5) HAMD score above 35 points; 6) losing the ability to walk alone due to the other diseases; 7) pregnant women, women who were in lactation period or potentially pregnant; 8) patients who were alcohol or drug addictive; 9) patients who were participating other clinical trial at the recruitment of having participated other clinical trial within 30 days before this study; 10) patients who were unable to cooperate with the study.

Design outcomes

Primary

MeasureTime frame
the difference value between the HAMA score at baseline and the HAMA score durint the rTMS intervention period;the difference value between the HAMD score at baseline and the HAMD score durint the rTMS intervention period;the difference value between the MARDS score at baseline and the MARDS score durint the rTMS intervention period;

Secondary

MeasureTime frame
the difference value between the PDQ-8 score at baseline and the PDQ-8 score durint the rTMS intervention period;the difference value between the CGI score at baseline and the CGI score durint the rTMS intervention period;the difference value between the PDSS-2 score at baseline and the PDSS-2 score durint the rTMS intervention period;the difference value between the ESS score at baseline and the ESS score during the rTIM intervention period;the difference value betwen the RBDQ-HK score at baseline and the RBDQ-HK score during the rTMS intervention period;the difference value between the LARS score at baseline and the LARS score during the rTIMS intervention period;the difference value between the IRLSSG score at baseline and the IRLSSG score during the rTMS intervention period;

Countries

China

Contacts

Public ContactQi Chen

Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine

doctorqi@126.com+86 21-25077504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026